NDAINTRA-ARTERIALSOLUTION
Approved
Jun 2018
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
4/8 — Partial
ABLYSINOL (alcohol) by Gen Pharmaceuticals is intra-arterial catheter into a target septal vessel, which causes the hypertrophied septum to thin. First approved in 2018.
Drug data last refreshed 16h ago · AI intelligence enriched 1mo ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ABLYSINOL (alcohol) is an intra-arterial solution approved in 2018 for the treatment of hypertrophic cardiomyopathy. It works by delivering alcohol via catheter into a target septal vessel, causing the hypertrophied septum to thin and improve cardiac function. This is a specialized interventional cardiology product with a narrow, well-defined patient population.
Peak
Product is at peak lifecycle stage with moderate competitive pressure (30%), suggesting stable commercial operations but limited expansion opportunities for sales and marketing teams.
Mechanism of Action
intra-arterial catheter into a target septal vessel, which causes the hypertrophied septum to thin.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Pregnenolone to Target Concurrent PTSD and Stress Induced Alcohol Use in Veterans: A Dose Finding Study
Started Jan 2027
40 enrolled
Alcohol Use Disorder (AUD)Post Traumatic Stress Disorder (PTSD)
Daridorexant for Alcohol Use Disorder
Started Jan 2027
150 enrolled
Alcohol Use Disorder
Intravenous Acetate as an Adjunctive Treatment for Alcohol Withdrawal in Hospitalized Patients
Started Nov 2026
75 enrolled
Alcohol WithdrawalAlcohol AbstinenceAlcohol Use Disorder
Alcohol Neurolysis and Capsaicin for Postamputation Pain (PAP)
Started Oct 2026
120 enrolled
Postamputation Pain
High-Plant-Protein-Diet or High-Animal-Protein-Diet for Improving Alcoholic Fatty Liver Disease
Started Oct 2026
74 enrolled
Alcohol-associated Fatty Liver Disease
Worked on ABLYSINOL at Gen Pharmaceuticals? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.